<?xml version="1.0" encoding="UTF-8"?>
<p>SFJD (China State Food and Drug Administration—drug approval number: Z20090047, executive standard number: YBZ00652009) was provided by Anhui Jiren Pharmaceutical CO., LTD (Anhui, China). The preparation and quality control of SFJD has been performed by our previous study (11), and the components of SFJD were detected by high-performance liquid chromatography (HPLC) (
 <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01545/suppl_file/ao0c01545_si_001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">Supporting Information</ext-link>). Oseltamivir phosphate capsules (Lot: SH0037) were purchased from Roche Pharmaceutical Co., Ltd. (Shanghai, China). Antibodies against phospho-NF-κB p65 (p-NF-κB p65) and NF-κB p65 were purchased from Abcam (Cambridge, UK). Phospho-IRF3 (
 <italic>p</italic>-IRF3), IRF3, phosphosignal transducers and activators of transcription 1 (p-STAT1), STAT1, phospho-TANK-binding kinase 1 (
 <italic>p</italic>-TBK1), TBK1 phosphomitogen-activated protein kinases (
 <italic>p</italic>-MAPK P38), MAPK P38, phospho-extracellular regulated protein kinases (
 <italic>p</italic>-ERK), ERK, and β-actin antibodies were purchased from Santa Cruz Biotechnology (CA, USA).
</p>
